lurasidone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4168 | 367514-87-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin Type 2 (5HT2A) receptor antagonism.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 60 | mg | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 28, 2010 | FDA | SUNOVION PHARMS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 479.21 | 41.16 | 127 | 817 | 20907 | 2336234 |
| Blood prolactin abnormal | 268.74 | 41.16 | 35 | 909 | 75 | 2357066 |
| Sedation | 265.61 | 41.16 | 56 | 888 | 3306 | 2353835 |
| Anosognosia | 263.18 | 41.16 | 33 | 911 | 44 | 2357097 |
| Sexual dysfunction | 260.69 | 41.16 | 39 | 905 | 293 | 2356848 |
| Dystonia | 258.71 | 41.16 | 51 | 893 | 2143 | 2354998 |
| Suicide attempt | 211.99 | 41.16 | 59 | 885 | 11223 | 2345918 |
| Metabolic disorder | 201.40 | 41.16 | 34 | 910 | 584 | 2356557 |
| Disturbance in social behaviour | 200.38 | 41.16 | 29 | 915 | 167 | 2356974 |
| Dyskinesia | 192.71 | 41.16 | 46 | 898 | 4743 | 2352398 |
| Personality change | 154.92 | 41.16 | 29 | 915 | 912 | 2356229 |
| Psychotic disorder | 127.89 | 41.16 | 33 | 911 | 4646 | 2352495 |
| Weight increased | 115.51 | 41.16 | 44 | 900 | 22293 | 2334848 |
| Schizophrenia | 109.04 | 41.16 | 23 | 921 | 1336 | 2355805 |
| Mania | 106.06 | 41.16 | 25 | 919 | 2415 | 2354726 |
| Blood glucose increased | 104.33 | 41.16 | 35 | 909 | 12255 | 2344886 |
| Drug ineffective | 104.30 | 41.16 | 66 | 878 | 101558 | 2255583 |
| Akathisia | 104.27 | 41.16 | 23 | 921 | 1651 | 2355490 |
| Insurance issue | 95.34 | 41.16 | 17 | 927 | 403 | 2356738 |
| Off label use | 93.77 | 41.16 | 55 | 889 | 73543 | 2283598 |
| Toxicity to various agents | 89.61 | 41.16 | 41 | 903 | 32713 | 2324428 |
| Blood prolactin increased | 85.23 | 41.16 | 18 | 926 | 1049 | 2356092 |
| Condition aggravated | 68.90 | 41.16 | 34 | 910 | 31945 | 2325196 |
| Suicidal ideation | 64.96 | 41.16 | 24 | 920 | 11063 | 2346078 |
| Agitation | 61.36 | 41.16 | 23 | 921 | 11028 | 2346113 |
| Swollen tongue | 56.47 | 41.16 | 18 | 926 | 5325 | 2351816 |
| Adverse drug reaction | 56.23 | 41.16 | 20 | 924 | 8263 | 2348878 |
| Pregnancy | 53.22 | 41.16 | 19 | 925 | 7930 | 2349211 |
| Bipolar disorder | 49.42 | 41.16 | 12 | 932 | 1306 | 2355835 |
| Angioedema | 48.50 | 41.16 | 18 | 926 | 8378 | 2348763 |
| Parkinsonism | 47.83 | 41.16 | 12 | 932 | 1493 | 2355648 |
| Tardive dyskinesia | 46.35 | 41.16 | 12 | 932 | 1692 | 2355449 |
| Tremor | 44.48 | 41.16 | 22 | 922 | 20639 | 2336502 |
| Depression | 43.53 | 41.16 | 24 | 920 | 28108 | 2329033 |
| Anxiety | 42.58 | 41.16 | 24 | 920 | 29335 | 2327806 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 136.78 | 44.89 | 46 | 536 | 16266 | 1729933 |
| Psychotic disorder | 125.09 | 44.89 | 33 | 549 | 5023 | 1741176 |
| Schizophrenia | 94.09 | 44.89 | 22 | 560 | 2024 | 1744175 |
| Anosognosia | 92.85 | 44.89 | 13 | 569 | 55 | 1746144 |
| Hallucination, auditory | 67.70 | 44.89 | 17 | 565 | 2100 | 1744099 |
| Drug ineffective | 63.68 | 44.89 | 41 | 541 | 63760 | 1682439 |
| Dystonia | 63.53 | 44.89 | 16 | 566 | 1998 | 1744201 |
| Blood prolactin abnormal | 62.69 | 44.89 | 9 | 573 | 47 | 1746152 |
| Off label use | 62.61 | 44.89 | 34 | 548 | 38537 | 1707662 |
| Aggression | 60.22 | 44.89 | 21 | 561 | 8094 | 1738105 |
| Dyskinesia | 57.76 | 44.89 | 17 | 565 | 3802 | 1742397 |
| Tremor | 57.25 | 44.89 | 23 | 559 | 13108 | 1733091 |
| Weight increased | 53.34 | 44.89 | 21 | 561 | 11336 | 1734863 |
| Mania | 52.92 | 44.89 | 14 | 568 | 2119 | 1744080 |
| Sedation | 50.74 | 44.89 | 15 | 567 | 3402 | 1742797 |
| Disturbance in social behaviour | 50.38 | 44.89 | 9 | 573 | 211 | 1745988 |
| Metabolic disorder | 48.23 | 44.89 | 10 | 572 | 522 | 1745677 |
| Suicidal ideation | 48.01 | 44.89 | 18 | 564 | 8500 | 1737699 |
| Paranoia | 47.88 | 44.89 | 13 | 569 | 2168 | 1744031 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AE05 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D058669 | Adrenergic alpha-2 Receptor Antagonists |
| FDA EPC | N0000175430 | Atypical Antipsychotic |
| MeSH PA | D000317 | Adrenergic alpha-Antagonists |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D065127 | Dopamine D2 Receptor Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D058830 | Serotonin 5-HT2 Receptor Antagonists |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D012702 | Serotonin Antagonists |
| CHEBI has role | CHEBI:37887 | adrenergic antagonist |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonist |
| CHEBI has role | CHEBI:48279 | serotonergic antagonist |
| CHEBI has role | CHEBI:65191 | second generation antipsychotic |
| MeSH PA | D014149 | Tranquilizing Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Bipolar affective disorder, current episode depression | indication | 191627008 | DOID:3312 |
| Suicidal thoughts | contraindication | 6471006 | |
| Weight gain finding | contraindication | 8943002 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Lowered convulsive threshold | contraindication | 19260006 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Dysphagia | contraindication | 40739000 | |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Hepatic failure | contraindication | 59927004 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Tardive dyskinesia | contraindication | 102449007 | |
| Seizure disorder | contraindication | 128613002 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
| Transient ischemic attack | contraindication | 266257000 | DOID:224 |
| Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
| Syncope | contraindication | 271594007 | |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Senile dementia with psychosis | contraindication | 371026009 | |
| Cardiovascular event risk | contraindication | 395112001 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.38 | Basic |
| pKa2 | 0.27 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | Jan. 27, 2020 | NEW PATIENT POPULATION |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | Jan. 27, 2020 | REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | Jan. 27, 2020 | NEW PATIENT POPULATION |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | Jan. 27, 2020 | REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | Jan. 27, 2020 | NEW PATIENT POPULATION |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | Jan. 27, 2020 | REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | Jan. 27, 2020 | NEW PATIENT POPULATION |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | July 27, 2020 | PEDIATRIC EXCLUSIVITY |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | July 27, 2020 | PEDIATRIC EXCLUSIVITY |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | July 27, 2020 | PEDIATRIC EXCLUSIVITY |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | July 27, 2020 | PEDIATRIC EXCLUSIVITY |
| 20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | March 5, 2021 | NEW PATIENT POPULATION |
| 40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | March 5, 2021 | NEW PATIENT POPULATION |
| 60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | March 5, 2021 | NEW PATIENT POPULATION |
| 80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | March 5, 2021 | NEW PATIENT POPULATION |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.00 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 9.33 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 9.31 | DRUG LABEL | ||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.97 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.20 | DRUG LABEL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 7.39 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.69 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 8.17 | IUPHAR | ||||
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.77 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D000069056 | MESH_DESCRIPTOR_UI |
| C2954611 | UMLSCUI |
| D04820 | KEGG_DRUG |
| 22IC88528T | UNII |
| 8247 | INN_ID |
| 715585000 | SNOMEDCT_US |
| 1040028 | RXNORM |
| d07705 | MMSL |
| 4030301 | VANDF |
| 013606 | NDDF |
| 703115008 | SNOMEDCT_US |
| 367514-88-3 | SECONDARY_CAS_RN |
| DB08815 | DRUGBANK_ID |
| CHEBI:70735 | CHEBI |
| CHEMBL1237021 | ChEMBL_ID |
| CHEMBL1615372 | ChEMBL_ID |
| 213046 | PUBCHEM_CID |
| 7461 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-302 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 20 sections |
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-304 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 20 sections |
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-306 | TABLET, FILM COATED | 60 mg | ORAL | NDA | 20 sections |
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-308 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 20 sections |
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-312 | TABLET, FILM COATED | 120 mg | ORAL | NDA | 20 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-082 | TABLET, COATED | 60 mg | ORAL | ANDA | 20 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-879 | TABLET, COATED | 20 mg | ORAL | ANDA | 20 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-880 | TABLET, COATED | 40 mg | ORAL | ANDA | 20 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-881 | TABLET, COATED | 80 mg | ORAL | ANDA | 20 sections |
| Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-882 | TABLET, COATED | 120 mg | ORAL | ANDA | 20 sections |
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1812 | TABLET, FILM COATED | 60 mg | ORAL | NDA | 20 sections |
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1824 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 20 sections |
| Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1936 | TABLET, FILM COATED | 120 mg | ORAL | NDA | 20 sections |